Charles River, Aitia in deal to use Logica in discovery for NDDs, oncology

Charles River Laboratories and Aitia, a leader in the application of Causal AI and Digital Twins, announced a strategic agreement that gives Aitia access to Logica, Charles River’s Artificial Intelligence powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.Under the terms of the agreement, Aitia will deploy Logica across their portfolio of novel drug targets with the aim of creating and advancing drug candidates for neurological indications, including Alzheimer’s, Parkinson’s, and Huntington’s diseases and cancers, including prostate cancer and multiple myeloma. According to the World Health Organization , Alzheimer’s disease the most common form of dementia, affects 33M people globally, while Parkinson’s disease impacts 8.5M, and it is estimated that Huntington’s disease affects approximatively 1 in 10,000 people worldwide. There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year. In the field of oncology, there are approximately 1.4M new cases of prostate cancer and 160,000 new cases of multiple myeloma reported globally each year. Each cancer presents unique challenges with acquired resistance to novel therapies and corresponding rates of overall survival.